Search results for "VOLUME"

showing 10 items of 1932 documents

Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease

1988

In a six-month multicenter feasibility and safety study, 20 patients, who all had a congenital deficiency of alpha-1-protease inhibitor (A1PI) of the PiZ phenotype accompanied by a chronic obstructive lung disease, were treated with human-plasma-derived A1PI. A weekly dose of 60 mg/kg, administered intravenously, was shown to be sufficient to maintain patient serum levels above the threshold limit of 35 percent, the serum level of healthy persons of the MZ phenotype. This is supposed to be the minimal effective level for protection against the elastolytic attack of the lung and, therefore, satisfies one of the most important criteria of feasibility of long-term replacement therapy. The glob…

AdultMalealpha 1-Antitrypsin DeficiencymedicineHumansLung Diseases ObstructiveInfusions IntravenousAgedRadial immunodiffusionClinical Trials as TopicLungPancreatic Elastasebiologybusiness.industryBlood ProteinsGeneral MedicineMiddle AgedOuchterlony double immunodiffusionTrypsinmedicine.diseaseAlpha-1 Protease Inhibitor DeficiencyObstructive lung diseasePhenotypemedicine.anatomical_structureImmunologybiology.proteinFemaleAntibodyLung Volume MeasurementsbusinessNephelometrymedicine.drugThe American Journal of Medicine
researchProduct

Thyrotropin-releasing hormone has stimulatory effects on ventilation in humans

1991

Thyrotropin-releasing hormone (TRH) stimulates pituitary thyrotropin synthesis and release and also regulates autonomic nervous system functions by acting as a neuromodulator and neurotransmitter. In experimental animals a stimulation of ventilation by thyrotropin-releasing hormone was shown when applied at central nervous system sites that affect respiratory motor output. It was the goal of our study to investigate the respiratory properties of thyrotropin-releasing hormone on basal and stimulated (i.e. CO2-rebreathing) conditions following systemic thyrotropin-releasing hormone application in healthy humans. Thyrotropin-releasing hormone (200 micrograms, 400 micrograms intravenous) initia…

AdultMaleendocrine systemmedicine.medical_specialtyAdolescentRespiratory ratePhysiologyStatistics as TopicCentral nervous systemThyrotropin-releasing hormoneInternal medicinemedicineHumansRespiratory systemThyrotropin-Releasing Hormonebusiness.industryRespirationRespiratory Function TestsAutonomic nervous systemmedicine.anatomical_structureEndocrinologyBreathingFemalebusinessRespiratory minute volumeHormoneActa Physiologica Scandinavica
researchProduct

Effects of corticotropin-releasing hormone on respiratory parameters during sleep in normal men.

2009

Corticotropin-releasing hormone (CRH) is well-known to be a centrally acting respiratory stimulant after systemic application both in healthy subjects and in patients suffering from respiratory failure. In order to study the effects of CRH on sleep EEG and respiratory parameters during sleep, 14 healthy male volunteers were investigated in a single-blind placebo controlled design. After an adaptation night, polysomnography was performed during two successive nights between 23.00 hrs. and 7.00 hrs. During one night placebo was applied, on the other 50 μg ovine CRH was administered intravenously as a bolus every hour from 0.00 hrs. to 6.00 hrs. For the assessment of respiration, blood oxygen …

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneCorticotropin-Releasing HormoneEndocrinology Diabetes and MetabolismSleep REMPolysomnographyPlacebosCorticotropin-releasing hormoneEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodSleep and breathingInternal medicineInternal MedicinemedicineHumansRespiratory systemTidal volumeSlow-wave sleepmedicine.diagnostic_testbusiness.industryElectromyographyRespirationElectroencephalographyGeneral MedicineThoraxOxygenKineticsEndocrinologyRespiratory failureAnalepticAnesthesiabusinessSleephormones hormone substitutes and hormone antagonistsExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Blue-yellow deficiency in workers exposed to low concentrations of organic solvents

1997

Objectives: To evaluate the effects of low concentrations of organic solvents on color vision. Methods: Color vision was examined in 24 workers exposed to mixtures of solvents and in 24 control subjects. Exposure to mixtures was below the threshold-limit values. Color vision ability was assessed using the Ishihara plates (to screen for congenital dyschromatopsia), the Farnsworth panel D-15 test, the Lanthony desaturated panel D-15 test, and the Standard Pseudoisochromatic Plates part 2 (SPP2 test). Results: The comparatively less sensitive Farnsworth panel D-15 test failed to show any difference between the groups, but the Lanthony panel D-15 desaturated test as well as the SPP2 test showed…

AdultMalegenetic structuresbusiness.industryColor visionOrganic solventLow dosePublic Health Environmental and Occupational HealthColor Vision DefectsControl subjectseye diseasesVision disorderLogistic ModelsCase-Control StudiesOccupational ExposureSolventsHumansMedicineOccupational exposureFood sciencemedicine.symptombusinessDyschromatopsiaVolume concentrationPsychophysiologyInternational Archives of Occupational and Environmental Health
researchProduct

Hippocampal subfields predict positive symptoms in schizophrenia : First evidence from brain morphometry

2012

Alterations of hippocampal anatomy have been reported consistently in schizophrenia. Within the present study, we used FreeSurfer to determine hippocampal subfield volumes in 21 schizophrenic patients. A negative correlation between PANSS-positive symptom score and bilateral hippocampal subfield CA2/3 as well as CA1 volume was found on high-resolution magnetic resonance images. Our observation opens the gate for advanced investigation of the commonly reported hippocampal abnormalities in schizophrenia in terms of specific subfields.

AdultMalegenetic structureshippocampusFreeSurferHippocampusHippocampal formationCA1Cellular and Molecular NeurosciencemedicineImage Processing Computer-AssistedHumansddc:610Biological PsychiatryvolumetryPsychiatric Status Rating Scalesmedicine.diagnostic_testBrain morphometryMagnetic resonance imagingOrgan Sizemedicine.diseaseMagnetic Resonance ImagingJschizophreniaPsychiatry and Mental healthnervous systemCA2/3SchizophreniaPsychiatric status rating scalesOriginal ArticleFemaleNegative correlationPsychologyNeuroscienceSymptom score
researchProduct

Quantitative analysis of emphysema in 3D using MDCT: Influence of different reconstruction algorithms

2008

Abstract Purpose The aim of the study was to compare the influence of different reconstruction algorithms on quantitative emphysema analysis in patients with severe emphysema. Material and methods Twenty-five patients suffering from severe emphysema were included in the study. All patients underwent inspiratory MDCT (Aquilion-16, slice thickness 1/0.8 mm). The raw data were reconstructed using six different algorithms: bone kernel with beam hardening correction (BHC), soft tissue kernel with BHC; standard soft tissue kernel, smooth soft tissue kernel (internal reference standard), standard lung kernel, and high-convolution kernel. The only difference between image data sets was the algorith…

AdultMalegenetic structuresinformation scienceAbsolute differenceStatistics NonparametricPulmonary function testingImaging Three-DimensionalHumansMedicinenatural sciencesRadiology Nuclear Medicine and imagingLung volumesAgedPhantoms Imagingbusiness.industryfood and beveragesSoft tissueReconstruction algorithmGeneral MedicineMiddle AgedRespiratory Function TestsPulmonary EmphysemaKernel (statistics)Radiographic Image Interpretation Computer-AssistedFemaleTomographyTomography X-Ray ComputedbusinessNuclear medicineAlgorithmQuantitative analysis (chemistry)AlgorithmsSoftwareEuropean Journal of Radiology
researchProduct

The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies.

1976

The pharmacodynamics and pharmacokinetics of the optical enantiomers of phenprocoumon were studied in 5 normal subjects and compared to the racemic mixture. Each subject received a single oral dose of 0.6 mg/kg of racemic, S(-), and R(+) phenprocoumon. S(-) phenprocoumon was 1.6 to 2.6 times as a potent as R(+) phenprocoumon when the area under the effect/time curve was used to quantify the total anticoagulant effect per dose. Comparing the plasma concentrations that elicited the same anticoagulant effect, S(-) phenprocoumon was 1.5 to 2.5 times as potent as R(+) phenprocoumon. The anticoagulant activity of the racemic mixture was between that of the enantiomers. There was no distinct diffe…

AdultMalemedicine.drug_classMetabolic Clearance RateIn Vitro TechniquesPhenprocoumonStructure-Activity RelationshipPharmacokineticsCoumarinsmedicineHumansPharmacology (medical)Serum AlbuminPharmacologyVolume of distributionChromatographyChemistryAnticoagulantAnticoagulantsStereoisomerismHuman serum albuminKineticsPharmacodynamicsPhenprocoumonProthrombin TimeRacemic mixtureEnantiomermedicine.drugProtein BindingClinical pharmacology and therapeutics
researchProduct

Influence of low temperature on bronchodilatation induced by terbutaline administered by metered dose or dry powder inhalers in asthmatics.

2000

Low temperatures may affect dose delivery efficacy and clinical effectiveness of medication aerosols. In this study we examine the effect of cold ambient temperature on the bronchodilatation produced by terbutaline delivered from a chlorofluorocarbon pressurized metered dose inhaler (pMDI) compared to a multi-dose dry powder inhaler (DPI). Fourteen stable asthmatics were studied on two consecutive days. On day 1, after measuring FEV1 at room temperature (22 degrees C), each patient was randomized to receive 500 microg of terbutaline delivered from pMDI or DPI stored for 24 h at 22 degrees C with FEV1 recorded 20 min post-dose; then, patients were placed in a chamber at -10 degrees C, and af…

AdultMalemedicine.drug_classTerbutalineCold storageBronchiBronchodilatorForced Expiratory VolumeAdministration InhalationmedicineTerbutalineHumansPharmacology (medical)PharmacologyDose-Response Relationship DrugCumulative doseChemistryInhalerAdrenergic beta-AgonistsMiddle AgedMetered-dose inhalerDry-powder inhalerAsthmaBronchodilator AgentsCold TemperatureBronchodilatationAnesthesiaFemalePowdersmedicine.drugFundamentalclinical pharmacology
researchProduct

Central obesity and hypertensionThe role of plasma endothelin

1996

Hypertension and central obesity are two conditions closely linked, but the mechanisms responsible for obesity-associated hypertension are still unclear. In the last few years, several studies addressed the role of endothelin-1 (ET-1) in the development and maintenance of hypertension. This study was designed to evaluate plasma ET-1 in normotensive and hypertensive central obese subjects compared with a lean healthy group. Our final goal was to analyze the relationship between plasma ET-1, blood pressure, and left ventricular structure and function in central obese subjects (both normotensives and hypertensives). ET-levels have been assessed by the radioimmunoassay method in 20 lean normote…

AdultMalemedicine.hormoneMean arterial pressuremedicine.medical_specialtyAmbulatory blood pressureMegalencephalic leukoencephalopathy with subcortical cystsRadioimmunoassayBody Mass IndexEndothelinsVentricular Dysfunction LeftHeart RateInternal medicineInternal MedicinemedicineHumansRadionuclide AngiographyEndothelin-1business.industryStroke VolumeStroke volumeBlood Pressure Monitoring Ambulatorymedicine.diseaseBody HeightObesity MorbidMean blood pressureBlood pressureEndocrinologyEchocardiographyHypertensionBody ConstitutionRegression AnalysisFemalebusinessBody mass indexAmerican Journal of Hypertension
researchProduct

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbi…

2008

Summary Background The treatment of allergic asthma by specific immunotherapy (SIT) is hampered by potential side-effects. Objective The aim of this study was to study the effect of omalizumab, a monoclonal anti-IgE antibody, in combination with SIT in patients with seasonal allergic rhinoconjunctivitis (SAR) and co-morbid seasonal allergic asthma (SAA) incompletely controlled by conventional pharmacotherapy. Methods A randomized, double-blind, placebo-controlled, multi-centre trial was performed to assess the efficacy and safety of omalizumab (Xolair®) vs. placebo in combination with depigmented SIT (Depigoid®) during the grass pollen season. Omalizumab or placebo was started 2 weeks befor…

AdultMalemedicine.medical_specialtyAdolescentCombination therapyImmunologyOmalizumabOmalizumabAntibodies Monoclonal HumanizedPlacebolaw.inventionYoung AdultPharmacotherapyDouble-Blind MethodRandomized controlled triallawForced Expiratory VolumeInternal medicineAnti-Allergic AgentsmedicineClinical endpointHumansImmunology and AllergyChildConjunctivitis AllergicAsthmaPlant Extractsbusiness.industryAntibodies MonoclonalRhinitis Allergic SeasonalAntigens PlantMiddle Agedmedicine.diseaseCombined Modality TherapyAsthmaAntibodies Anti-IdiotypicRespiratory Function TestsTreatment OutcomeDesensitization ImmunologicAsthma Control QuestionnaireQuality of LifePhysical therapyPollenFemalebusinessmedicine.drugClinical & Experimental Allergy
researchProduct